Evolent Health Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
74.7%projected annual EPS growth
Analyst Coverage
13analysts covering
FY Revenue (est.)
$2.5Bnext fiscal year
FY EPS (est.)
$0.20next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Medical Expense Ratio (MER) Quarterly9,330.0%Target: Approximately 93.0% for the full year 2026
Adjusted EBITDA Quarterly22.1MTarget: $110.0 million to $140.0 million for the full year 2026
Quarterly Revenue Quarterly496.2MTarget: $2.4 billion to $2.6 billion for the full year 2026
Watch Items
- Exchange Membership DeclineTrigger: Decline exceeding the anticipated 40% thresholdAction: Re-evaluate revenue targets and adjust operational cost structures to protect margins.
- Oncology and Specialty Care Launch PerformanceTrigger: Delays or operational friction in newly launched programs with Aetna and HighmarkAction: Deploy clinical and technical integration teams to stabilize delivery and secure contractual protections.
Research as of 19 Jun 2026